Lymphoma News

Belumosudil (REZUROCK, Kadmon Pharmaceuticals, LLC), is a kinase inhibitor for chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older.

On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

Milos Miljkovic, MD MSc of the National Cancer Institute Center for Cancer Research discusses the main differences between these types of ALCL, how they are diagnosed, and typical frontline therapies.

On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).

Krish Patel, MD of the Swedish Cancer Institute discusses how MRD is measured and what patients should know about testing for it.

LRF grantee Jason Romancik, MD of the Winship Cancer Institute discusses these treatment options and what factors patients should consider when deciding what's right for them.